Analyst Price Target is $145.20
▲ +60.80% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Ascendis Pharma A/S in the last 3 months. The average price target is $145.20, with a high forecast of $192.00 and a low forecast of $113.00. The average price target represents a 60.80% upside from the last price of $90.30.
Current Consensus is
The current consensus among 10 contributing investment analysts is to moderate buy stock in Ascendis Pharma A/S. This Moderate Buy consensus rating has held steady for over two years.
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.